Page last updated: 2024-11-05

ochracin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ochracin is a yellow mycotoxin produced by the fungus Aspergillus ochraceus. It has been shown to exhibit a range of biological effects, including immunosuppressive, cytotoxic, and genotoxic activities. Ochracin is a potent inhibitor of the enzyme dihydrofolate reductase, which is essential for the synthesis of DNA and RNA. This inhibition can lead to the disruption of cell growth and proliferation. Ochracin has also been shown to induce apoptosis in various cell lines, including cancer cells. The compound's potential toxicity and immunosuppressive effects have led to its classification as a food contaminant. Ochracin is studied to understand its toxic mechanisms and to develop strategies to mitigate its contamination in food products. Research is also being conducted to investigate the potential use of ochracin as a therapeutic agent in cancer treatment.'

ochracin: produced by Aspergillus alutaceus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID28516
CHEMBL ID226090
CHEBI ID38760
SCHEMBL ID13925643
SCHEMBL ID1230955
MeSH IDM0332726

Synonyms (38)

Synonym
ochracin
antibiotic bv-1
ao-2
3,4-dihydro-8-hydroxy-3-methylisocoumarin
antibiotic ao-2
bv-1
isocoumarin, 3,4-dihydro-8-hydroxy-3-methyl-
1h-2-benzopyran-1-one, 3,4-dihydro-8-hydroxy-3-methyl-
inchi=1/c10h10o3/c1-6-5-7-3-2-4-8(11)9(7)10(12)13-6/h2-4,6,11h,5h2,1h
CHEMBL226090 ,
chebi:38760 ,
alm-9
bdbm50208249
3-methyl-8-hydroxy-3,4-dihydroisocoumarin
8-hydroxy-3-methyl-3,4-dihydroisochromen-1-one
AKOS006228659
3,4-dihydro-8-hydroxy-3-methyl-1h-2-benzopyran-1-one
17397-85-2
8-hydroxy-3-methylisochroman-1-one
8-hydroxy-3-methyl-3,4-dihydro-1h-isochromen-1-one
3,4-dihydro-8-hydroxy-3-methyl-(1h)-2-benzopyran-1-one
SCHEMBL13925643
SCHEMBL1230955
3,4-dihydro-8-hydroxy-3-methyl-1h-2-benzopyran-1-one, (.+/-.)-
(.+/-.)-mellein
isocoumarin, 3,4-dihydro-8-hydroxy-3-methyl, (.+/-.)-
3-methyl-8-hydroxy-3,4-dihydro-1h-2-benzopyran-1-one
8-hydroxy-3-methyl-isochroman-1-one
(+/-)-mellein
1200-93-7
8-hydroxy-3-methyl-3,4-dihydro-1h-2-benzopyran-1-one
DTXSID60891794
Q6813065
STARBLD0003745
CS-0225132
E82508
EN300-1228708
Z1198723372
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isochromanes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase betaRattus norvegicus (Norway rat)IC50 (µMol)1,000.00003.70006.20008.5000AID287914
DNA polymerase delta catalytic subunitHomo sapiens (human)IC50 (µMol)1,000.00002.30002.30002.3000AID287916
DNA polymerase lambdaHomo sapiens (human)IC50 (µMol)316.00005.20005.30005.4000AID287918
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
DNA synthesis involved in DNA repairDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA replicationDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA-templated DNA replicationDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA repairDNA polymerase delta catalytic subunitHomo sapiens (human)
base-excision repair, gap-fillingDNA polymerase delta catalytic subunitHomo sapiens (human)
nucleotide-excision repair, DNA gap fillingDNA polymerase delta catalytic subunitHomo sapiens (human)
response to UVDNA polymerase delta catalytic subunitHomo sapiens (human)
cellular response to UVDNA polymerase delta catalytic subunitHomo sapiens (human)
fatty acid homeostasisDNA polymerase delta catalytic subunitHomo sapiens (human)
error-free translesion synthesisDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA biosynthetic processDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA replication proofreadingDNA polymerase delta catalytic subunitHomo sapiens (human)
double-strand break repair via homologous recombinationDNA polymerase lambdaHomo sapiens (human)
DNA replicationDNA polymerase lambdaHomo sapiens (human)
base-excision repair, gap-fillingDNA polymerase lambdaHomo sapiens (human)
nucleotide-excision repairDNA polymerase lambdaHomo sapiens (human)
double-strand break repair via nonhomologous end joiningDNA polymerase lambdaHomo sapiens (human)
somatic hypermutation of immunoglobulin genesDNA polymerase lambdaHomo sapiens (human)
DNA biosynthetic processDNA polymerase lambdaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
nucleotide bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
chromatin bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
damaged DNA bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA-directed DNA polymerase activityDNA polymerase delta catalytic subunitHomo sapiens (human)
protein bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
enzyme bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
metal ion bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
4 iron, 4 sulfur cluster bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
3'-5'-DNA exonuclease activityDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA bindingDNA polymerase lambdaHomo sapiens (human)
DNA-directed DNA polymerase activityDNA polymerase lambdaHomo sapiens (human)
protein bindingDNA polymerase lambdaHomo sapiens (human)
metal ion bindingDNA polymerase lambdaHomo sapiens (human)
5'-deoxyribose-5-phosphate lyase activityDNA polymerase lambdaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
chromosome, telomeric regionDNA polymerase delta catalytic subunitHomo sapiens (human)
nucleusDNA polymerase delta catalytic subunitHomo sapiens (human)
nucleoplasmDNA polymerase delta catalytic subunitHomo sapiens (human)
cytosolDNA polymerase delta catalytic subunitHomo sapiens (human)
membraneDNA polymerase delta catalytic subunitHomo sapiens (human)
aggresomeDNA polymerase delta catalytic subunitHomo sapiens (human)
delta DNA polymerase complexDNA polymerase delta catalytic subunitHomo sapiens (human)
nucleotide-excision repair complexDNA polymerase delta catalytic subunitHomo sapiens (human)
site of double-strand breakDNA polymerase lambdaHomo sapiens (human)
nucleusDNA polymerase lambdaHomo sapiens (human)
nucleoplasmDNA polymerase lambdaHomo sapiens (human)
nucleusDNA polymerase lambdaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID358845Inhibition of HCV protease2001Journal of natural products, Jan, Volume: 64, Issue:1
Circumdatin G, a new alkaloid from the fungus Aspergillus ochraceus.
AID287913Inhibition of calf DNA polymerase alpha2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
Nodulisporol and Nodulisporone, novel specific inhibitors of human DNA polymerase lambda from a fungus, Nodulisporium sp.
AID287917Inhibition of human DNA polymerase epsilon2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
Nodulisporol and Nodulisporone, novel specific inhibitors of human DNA polymerase lambda from a fungus, Nodulisporium sp.
AID287915Inhibition of human DNA polymerase gamma2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
Nodulisporol and Nodulisporone, novel specific inhibitors of human DNA polymerase lambda from a fungus, Nodulisporium sp.
AID287916Inhibition of human DNA polymerase delta2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
Nodulisporol and Nodulisporone, novel specific inhibitors of human DNA polymerase lambda from a fungus, Nodulisporium sp.
AID746671Inhibition of Hepatitis C virus protease2013European journal of medicinal chemistry, May, Volume: 63Recent advances in natural products from plants for treatment of liver diseases.
AID287918Inhibition of human DNA polymerase lambda2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
Nodulisporol and Nodulisporone, novel specific inhibitors of human DNA polymerase lambda from a fungus, Nodulisporium sp.
AID287914Inhibition of rat DNA polymerase beta2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
Nodulisporol and Nodulisporone, novel specific inhibitors of human DNA polymerase lambda from a fungus, Nodulisporium sp.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.70)18.2507
2000's11 (40.74)29.6817
2010's11 (40.74)24.3611
2020's4 (14.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index5.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]